

VIPR1 Blocking Peptide(C-term) Synthetic peptide Catalog # BP19704b

## Specification

## VIPR1 Blocking Peptide(C-term) - Product Information

Primary Accession Other Accession P32241 NP\_004615.2

## VIPR1 Blocking Peptide(C-term) - Additional Information

Gene ID 7433

**Other Names** Vasoactive intestinal polypeptide receptor 1, VIP-R-1, Pituitary adenylate cyclase-activating polypeptide type II receptor, PACAP type II receptor, PACAP-R-2, PACAP-R2, VPAC1, VIPR1

Target/Specificity The synthetic peptide sequence is selected from aa 320-334 of HUMAN VIPR1

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

#### Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

### VIPR1 Blocking Peptide(C-term) - Protein Information

Name VIPR1

**Function** This is a receptor for VIP. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. The affinity is VIP = PACAP-27 > PACAP-38.

**Cellular Location** Cell membrane; Multi-pass membrane protein.

Tissue Location

In lung, HT-29 colonic epithelial cells, Raji B- lymphoblasts. Lesser extent in brain, heart, kidney, liver and placenta. Not expressed in CD4+ or CD8+ T-cells. Expressed in the T- cell lines HARRIS, HuT 78, Jurkat and SUP-T1, but not in the T-cell lines Peer, MOLT-4, HSB and YT.



# VIPR1 Blocking Peptide(C-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

### <u>Blocking Peptides</u>

## VIPR1 Blocking Peptide(C-term) - Images

## VIPR1 Blocking Peptide(C-term) - Background

This gene encodes a receptor for vasoactive intestinal peptide, a small neuropeptide. Vasoactive intestinal peptide is involved in smooth muscle relaxation, exocrine and endocrine secretion, and water and ion flux in lung and intestinal epithelia. Its actions are effected through integral membrane receptors associated with a guanine nucleotide binding protein which activates adenylate cyclase.

### VIPR1 Blocking Peptide(C-term) - References

Mlakar, V., et al. Cancer Invest. 28(5):487-494(2010) Burian, B., et al. Peptides 31(4):603-608(2010) Cocco, E., et al. PLoS ONE 5 (8), E12067 (2010) : Yokoyama, K., et al. Nephron Clin Pract 115 (4), C237-C243 (2010) : Chakrabarti, B., et al. Autism Res 2(3):157-177(2009)